Sandoz launches FDA-approved denosumab biosimilars WYOST and Jubbonti in the US

From Nasdaq: 2025-06-02 01:36:00

Sandoz has launched WYOST and Jubbonti in the US, the first interchangeable FDA-approved denosumab biosimilars. These drugs are approved to treat all indications of XGEVA and Prolia. They have the same dosage form, route of administration, dosing regimen, and presentation as the reference medicines. Sandoz is offering comprehensive support resources for patients prescribed WYOST and Jubbonti, including reimbursement and financial assistance. For more health news, visit rttnews.com. Please note, the views expressed are those of the author and do not necessarily reflect those of Nasdaq, Inc.



Read more at Nasdaq: Sandoz Announces Availability Of WYOST And Jubbonti In The US